# EB-CAR30-NK

Source: https://onco.cc/drugs/eb-car30-nk/  
OnCo record `eb-car30-nk` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.

## Summary

EB-CAR30-NK is a CAR-NK cell therapy developed by Beijing Biotech. Its target is CD30. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in thymoma and thymic carcinoma. The largest, NCT07598955, plans to enrol 36 participants with primary completion expected 2027-06-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-NK cell therapy
- Mechanism: CAR-NK cell therapy directed at CD30, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of EB-CAR30-NK: https://clinicaltrials.gov/search?intr=EB-CAR30-NK

## Connected records

- cancers: [Thymic carcinoma](https://onco.cc/cancers/thymic-carcinoma/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/)
- targets: [CD30](https://onco.cc/targets/cd30/)
- trials: [Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma](https://onco.cc/trials/nct07598955/)

---
JSON: https://onco.cc/api/v1/entities/eb-car30-nk.json